Crewe Advisors’s Cytokinetics CYTK Stock Holding History

Crewe Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-36	Closed	-$2.29K	–	1067
2025 Q4	$2.29K	Hold	36	–	–	﹤0.01%	854
2025 Q3	$1.98K	Buy	+36	New	+$1.48K	﹤0.01%	853

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Crewe Advisors's CYTK Position: Q1 2026 in Review

Crewe Advisors sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 36 shares — an estimated $2.29K sold.

Crewe Advisors first reported a position in CYTK in Q3 2025 and held it in 2 quarters. The position peaked at $2.29K in Q4 2025. 440 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Crewe Advisors reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
Crewe Advisors sold 36 Cytokinetics shares in Q1 2026, an estimated $2.29K.
Crewe Advisors first reported a position in Cytokinetics in Q3 2025 and held it in 2 quarters.
Crewe Advisors's Cytokinetics position peaked at $2.29K in Q4 2025.
440 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Crewe Advisors's 13F filing for Q1 2026, filed 7 May 2026.